Safety of magnetic resonance imaging contrast agents.
Many of the MR examinations performed in the world each year are accompanied by administration of one of these frequently used intravenous contrast agents: Magnevist, Omniscan, and ProHance. Accordingly, MR practitioners must understand the basic pharmacokinetics, side effects, and the potential for adverse events for these contrast agents. Additionally, MR practitioners must know how to manage side effects and adverse events that may occur in association with the administration of contrast agents. Notably, the use of MR imaging contrast agents in special patient populations must be understood. This article discusses each of these important issues.
Shellock
F G
FG
University of Southern California School of Medicine and Shellock R & D Services, Inc., Los Angeles, California 90045, USA. frank.shellock@gte.net
Kanal
E
E
D000818:Animals; D003287:Contrast Media / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000633:toxicity; D004342:Drug Hypersensitivity / Q000209:etiology; D005119:Extravasation of Diagnostic and Therapeutic Materials; D005682:Gadolinium; D019786:Gadolinium DTPA / Q000009:adverse effects / Q000493:pharmacokinetics / Q000633:toxicity; D006571:Heterocyclic Compounds / Q000009:adverse effects / Q000493:pharmacokinetics / Q000633:toxicity; D006801:Humans; D008279:Magnetic Resonance Imaging; D009942:Organometallic Compounds / Q000009:adverse effects / Q000493:pharmacokinetics / Q000633:toxicity; D017410:Practice Guidelines as Topic; D012449:Safety
D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C062402:gadoteridol; C064925:gadodiamide; D005682:Gadolinium; D019786:Gadolinium DTPA